We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » USPTO to Decide on Patent Extension for AAV Tech Used in Novartis’ Zolgensma
USPTO to Decide on Patent Extension for AAV Tech Used in Novartis’ Zolgensma
The FDA won’t weigh in on whether Regenxbio may be granted a patent extension for its adeno-associated virus (AAV) technology used to produce Novartis’ blockbuster spinal muscular atrophy (SMA) therapy Zolgensma (onasemnogene abeparvovec).